The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.

Saved in:
Bibliographic Details
Title: The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Authors: Marr, Alexander R.1 (AUTHOR), Halpin, Madeline1 (AUTHOR), Corbin, Dominique L.1 (AUTHOR), Asemelash, Yerdanos1 (AUTHOR), Sher, Steven1 (AUTHOR), Gordon, Britten K.1 (AUTHOR), Whipp, Ethan C.1 (AUTHOR), Mitchell, Shaneice2 (AUTHOR), Harrington, Bonnie K.3 (AUTHOR), Orwick, Shelley1 (AUTHOR), Benrashid, Samon1 (AUTHOR), Goettl, Virginia M.1 (AUTHOR), Yildiz, Vedat4 (AUTHOR), Mitchell, Andrew D.1 (AUTHOR), Cahn, Olivia1 (AUTHOR), Mims, Alice S.1 (AUTHOR), Larkin, Karilyn T. M.1 (AUTHOR), Long, Meixao1 (AUTHOR), Blachly, James1,5 (AUTHOR), Woyach, Jennifer A.1,5 (AUTHOR)
Source: Experimental Hematology & Oncology. 3/4/2024, Vol. 13 Issue 1, p1-21. 21p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21623619
DOI:10.1186/s40164-024-00483-w